Our top pick for
Building a portfolio
Covetrus, Inc is a health information services business based in the US. Covetrus shares (CVET) are listed on the NASDAQ and all prices are listed in US Dollars. Covetrus employs 5,275 staff and has a trailing 12-month revenue of around USD$4.3 billion.
|52-week range||USD$7.51 - USD$40.775|
|50-day moving average||USD$31.3317|
|200-day moving average||USD$30.2494|
|Wall St. target price||USD$34.2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.3|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Covetrus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Covetrus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Covetrus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 41x. In other words, Covetrus shares trade at around 41x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Covetrus's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5172. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Covetrus's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Covetrus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$112 million.
The EBITDA is a measure of a Covetrus's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$4.3 billion|
|Gross profit TTM||USD$798 million|
|Return on assets TTM||-0.99%|
|Return on equity TTM||-1.2%|
|Market capitalisation||USD$4 billion|
TTM: trailing 12 months
There are currently 5.5 million Covetrus shares held short by investors – that's known as Covetrus's "short interest". This figure is 5.6% down from 5.8 million last month.
There are a few different ways that this level of interest in shorting Covetrus shares can be evaluated.
Covetrus's "short interest ratio" (SIR) is the quantity of Covetrus shares currently shorted divided by the average quantity of Covetrus shares traded daily (recently around 909065.66666667). Covetrus's SIR currently stands at 6. In other words for every 100,000 Covetrus shares traded daily on the market, roughly 6000 shares are currently held short.
However Covetrus's short interest can also be evaluated against the total number of Covetrus shares, or, against the total number of tradable Covetrus shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Covetrus's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Covetrus shares in existence, roughly 40 shares are currently held short) or 0.0631% of the tradable shares (for every 100,000 tradable Covetrus shares, roughly 63 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Covetrus.
Find out more about how you can short Covetrus stock.
We're not expecting Covetrus to pay a dividend over the next 12 months.
Over the last 12 months, Covetrus's shares have ranged in value from as little as $7.51 up to $40.775. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Covetrus's is 2.1105. This would suggest that Covetrus's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Covetrus, Inc. , together with its subsidiaries, operates as an animal-health technology and services company. It engages in the sale of animal-health consumable products, including proprietary and Covetrus branded products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, parasiticides, and vitamins and supplements to wholesale and retail customers. The company also offers value-added solutions that include, inventory management and e-commerce, as well as continuing education services for practitioners. In addition, it provides practice management software systems for veterinary practitioners and animal-health clinics, client communication services, reminders, data backup services, and hardware sales and support services. Further, the company engages in the distribution of finished goods pharmacy and specialty pharmaceutical compounding products, as well as shipping, manufacturer incentives, service fees, and data integration and support services. It serves animal-health and veterinary practices, and clinics in the companion-animal and equine markets primarily in North America, Europe, and the Asia Pacific.
Features, fees and complaints to consider before you apply for a T. Rowe Price account.
Steps to owning and managing ZTO, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZOM, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZKIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZION, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZNTL, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZGYH, with 24-hour and historical pricing before you buy.
Steps to owning and managing ZEAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing CTIB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.